Winksele, Belgium

Desire J Collen


Average Co-Inventor Count = 1.1

ph-index = 6

Forward Citations = 89(Granted Patents)


Location History:

  • Winksele, BE (1979 - 1986)
  • Louvain, BE (1988)
  • Winksele-Herent, BE (1992 - 1999)

Company Filing History:


Years Active: 1979-1999

Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovations of Desire J Collen

Introduction

Desire J Collen is a notable inventor based in Winksele, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of staphylokinase derivatives. With a total of 11 patents to his name, his work has the potential to impact medical treatments, especially in the area of arterial thrombosis.

Latest Patents

Collen's latest patents focus on the identification, production, and use of new staphylokinase derivatives. The methods involve preparing a DNA fragment that includes the coding sequence of staphylokinase, performing in vitro site-directed mutagenesis, and cloning the mutated DNA fragment into a suitable vector. The transformed host cells are then cultured to express the DNA fragment. His inventions also encompass pharmaceutical compositions that include these staphylokinase derivatives, aimed at treating arterial thrombosis.

Career Highlights

Throughout his career, Desire J Collen has worked with various organizations, including Leuven Research & Development Vzw. His innovative approaches and research have led to advancements in the production of staphylokinase derivatives, showcasing his expertise in molecular biology and genetic engineering.

Collaborations

Some of his notable collaborators include Dingeman C Rijken and Osamu Matsuo. Their combined efforts have contributed to the successful development of his patented technologies.

Conclusion

Desire J Collen's work exemplifies the intersection of innovation and medical science. His contributions to the field of biotechnology through his patents on staphylokinase derivatives highlight the importance of research in developing new treatments for critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…